Yibin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yibin Deng has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Jiachun Lu
School of public health, Guangzhou medical university, Guangzhou, China
70 shared publications - Binbin Guo
Department of Genetics, School of Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China
65 shared publications - Fanrong Li
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications - Jian Zheng
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
65 shared publications - Jieqiong Deng
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications - Jieyu Wang
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications
Latest Publications
- 22 February 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1399, 345290
Machine learning-assisted sensor array based on CeO2 nanozymes for intelligent recognition of multiple synthetic phenolic antioxidants
- 22 February 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1399, 345290
Machine learning-assisted sensor array based on CeO2 nanozymes for intelligent recognition of multiple synthetic phenolic antioxidants
- Open Access
Study on the mortality risk and predictive model for COVID-19 inpatients with pneumonia manifestations
Background: In 2020, COVID-19 posed a major threat to global public health in a remarkably short period. Although the WHO declared an end to the emergency phase in May 2023, a considerable proportion of recovered cases experience medium- and long-term effects, which pose ongoing health challenges to society. Therefore, it remains necessary to conduct relevant research in the post-epidemic era to explore the risk factors for death in COVID-19 inpatients. Methods: We determined the mortality of COVID-19 inpatients with pneumonia manifestations through one-year follow-up, utilizing real-world data from three medical centers. Clinical characteristics associated with mortality risk were analyzed by logistic regression. Then, the dataset was randomly partitioned into three sets at a ratio of 4:2:4. Three machine learning algorithms were employed to develop and validate a mortality risk predictive model for COVID-19 inpatients, and a web-based visualization tool was created. Results: There were 100 fatalities among the 1,693 samples included in this study. Meanwhile, we identified 37 factors correlated with increased mortality risk in COVID-19 inpatients with pneumonia manifestations. Ultimately, we developed a mortality risk predictive model using the random forest algorithm, which demonstrated superior predictive performance (AUC=0.907, 95% CI=0.849-0.957). Conclusions: This study reports a mortality rate of 5.9% for COVID-19 inpatients with pneumonia manifestations. The high-performance mortality risk prediction model obtained in this study provides important practical guidance for monitoring the mortality risks of COVID-19 inpatients with pneumonia manifestations.
Open AccessStudy on the mortality risk and predictive model for COVID-19 inpatients with pneumonia manifestations
Background: In 2020, COVID-19 posed a major threat to global public health in a remarkably short period. Although the WHO declared an end to the emergency phase in May 2023, a considerable proportion of recovered cases experience medium- and long-term effects, which pose ongoing health challenges to society. Therefore, it remains necessary to conduct relevant research in the post-epidemic era to explore the risk factors for death in COVID-19 inpatients. Methods: We determined the mortality of COVID-19 inpatients with pneumonia manifestations through one-year follow-up, utilizing real-world data from three medical centers. Clinical characteristics associated with mortality risk were analyzed by logistic regression. Then, the dataset was randomly partitioned into three sets at a ratio of 4:2:4. Three machine learning algorithms were employed to develop and validate a mortality risk predictive model for COVID-19 inpatients, and a web-based visualization tool was created. Results: There were 100 fatalities among the 1,693 samples included in this study. Meanwhile, we identified 37 factors correlated with increased mortality risk in COVID-19 inpatients with pneumonia manifestations. Ultimately, we developed a mortality risk predictive model using the random forest algorithm, which demonstrated superior predictive performance (AUC=0.907, 95% CI=0.849-0.957). Conclusions: This study reports a mortality rate of 5.9% for COVID-19 inpatients with pneumonia manifestations. The high-performance mortality risk prediction model obtained in this study provides important practical guidance for monitoring the mortality risks of COVID-19 inpatients with pneumonia manifestations.
- Open Access
- 10 January 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Biological aging, a mediator between smoking and chronic obstructive pulmonary disease: evidence from a hospital-based cohort study in China
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity, with aging and smoking as key risk factors. However, the mediating rol
- 10 January 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessBiological aging, a mediator between smoking and chronic obstructive pulmonary disease: evidence from a hospital-based cohort study in China
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity, with aging and smoking as key risk factors. However, the mediating rol
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 2, figure 3, and figure 5
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Related information to figure 2, figure 3, and figure 5
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Primary clinical and histological characteristics of 67 study patients
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Primary clinical and histological characteristics of 67 study patients
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
The genomic position of the predicted ORFs of the six lncRNAs
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
The genomic position of the predicted ORFs of the six lncRNAs
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of LINC00887 and ACLY-BP cDNA
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from LncRNA-Encoded Micropeptide ACLY-BP Drives Lipid Deposition and Cell Proliferation in Clear Cell Renal Cell Carcinoma via Maintenance of ACLY Acetylation
Sequences of LINC00887 and ACLY-BP cDNA